ATE122894T1 - Verwendung und zusammensetzung zur verbesserung des ''targeting'' von antikörpern, antikörperteilen, sowie konjugate derselben. - Google Patents

Verwendung und zusammensetzung zur verbesserung des ''targeting'' von antikörpern, antikörperteilen, sowie konjugate derselben.

Info

Publication number
ATE122894T1
ATE122894T1 AT87907199T AT87907199T ATE122894T1 AT E122894 T1 ATE122894 T1 AT E122894T1 AT 87907199 T AT87907199 T AT 87907199T AT 87907199 T AT87907199 T AT 87907199T AT E122894 T1 ATE122894 T1 AT E122894T1
Authority
AT
Austria
Prior art keywords
antibodies
peptide
mammal
specific
fragments
Prior art date
Application number
AT87907199T
Other languages
English (en)
Inventor
Paul G Abrams
Robert W Schroff
Alton C Morgan Jr
Original Assignee
Neorx Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Neorx Corp filed Critical Neorx Corp
Application granted granted Critical
Publication of ATE122894T1 publication Critical patent/ATE122894T1/de

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K16/00Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C07K16/3053Skin, nerves, brain
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6835Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
    • A61K47/6851Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a determinant of a tumour cell
    • A61K47/6865Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a determinant of a tumour cell the tumour determinant being from skin, nerves or brain cancer cell
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Cell Biology (AREA)
  • Medicinal Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Oncology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Neurosurgery (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
AT87907199T 1986-10-09 1987-10-09 Verwendung und zusammensetzung zur verbesserung des ''targeting'' von antikörpern, antikörperteilen, sowie konjugate derselben. ATE122894T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US91717686A 1986-10-09 1986-10-09

Publications (1)

Publication Number Publication Date
ATE122894T1 true ATE122894T1 (de) 1995-06-15

Family

ID=25438446

Family Applications (1)

Application Number Title Priority Date Filing Date
AT87907199T ATE122894T1 (de) 1986-10-09 1987-10-09 Verwendung und zusammensetzung zur verbesserung des ''targeting'' von antikörpern, antikörperteilen, sowie konjugate derselben.

Country Status (8)

Country Link
EP (1) EP0288520B1 (de)
JP (1) JPH01501476A (de)
AT (1) ATE122894T1 (de)
AU (1) AU616161B2 (de)
CA (1) CA1340312C (de)
DE (1) DE3751319T2 (de)
DK (1) DK314688A (de)
WO (1) WO1988002594A2 (de)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5202252A (en) * 1982-03-05 1993-04-13 Houston Biotechnology Inc. Monoclonal antibodies against lens epithelial cells and methods for preventing proliferation of remnant lens epithelial cells after extracapsular extraction
US5616122A (en) * 1986-11-04 1997-04-01 Baylor College Of Medicine Methods and compositions for preventing secondary cataracts
DE68924783T2 (de) * 1988-09-30 1996-03-28 Neorx Corp Wässrige additivsysteme, verfahren und polymerteilchen.
US5066789A (en) * 1988-09-30 1991-11-19 Neorx Corporation Targeting substance-diagnostic/therapeutic agent conjugates having Schiff base linkages
FR2639231A1 (fr) * 1988-11-23 1990-05-25 Merieux Inst Utilisation de fragments fc d'immunoglobulines g humaines, de peptides analogues du fragment fc, ou d'immunoglobulines g humaines dans l'obtention d'un medicament preparatoire a l'administration chez l'homme, dans un but therapeutique ou de diagnostic, d'anticorps monoclonaux
US4986979A (en) * 1989-03-14 1991-01-22 Neorx Corporation Imaging tissue sites of inflammation
DE69026387T2 (de) * 1989-09-29 1996-11-28 Neorx Corp., Seattle, Wash. Reduktion der nichtzielspezifischen retention von immunokonjugaten und ihren metaboliten
DE69420137T2 (de) 1993-06-03 1999-12-23 Therapeutic Antibodies, Inc. Herstellung von antikörperfragmenten
JP4053596B2 (ja) 1995-11-03 2008-02-27 ザ・バインディング・サイト・リミテッド 抗体の産生、及び抗体を含む医療的使用
JP5817034B2 (ja) 2007-12-26 2015-11-18 バイオテスト・アクチエンゲゼルシヤフト Cd138を標的とする免疫複合体及びその使用
BRPI0821417A2 (pt) 2007-12-26 2015-06-16 Biotest Ag Método para diminuir a adesão de células de estroma a células tumorais que expressam cd138 em células tumorais de um indivíduo em necessidade do mesmo
HRP20140604T1 (hr) 2007-12-26 2014-09-12 Biotest Ag Sredstva koja djeluju na cd138 i njihova upotreba
EP2238169A1 (de) * 2007-12-26 2010-10-13 Biotest AG Verfahren zur verminderung der zytotoxischen nebenwirkungen und zur erhöhung der wirksamkeit von immunkonjugaten

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4664911A (en) * 1983-06-21 1987-05-12 Board Of Regents, University Of Texas System Immunotoxin conjugates employing toxin B chain moieties

Also Published As

Publication number Publication date
DK314688D0 (da) 1988-06-09
CA1340312C (en) 1999-01-12
AU8158787A (en) 1988-05-06
DE3751319D1 (de) 1995-06-29
EP0288520A1 (de) 1988-11-02
AU616161B2 (en) 1991-10-24
JPH01501476A (ja) 1989-05-25
WO1988002594A2 (en) 1988-04-21
DE3751319T2 (de) 1996-02-29
DK314688A (da) 1988-08-08
EP0288520B1 (de) 1995-05-24

Similar Documents

Publication Publication Date Title
DE3751319D1 (de) VERWENDUNG UND ZUSAMMENSETZUNG ZUR VERBESSERUNG DES "TARGETING" VON ANTIKöRPERN, ANTIKöRPERTEILEN, SOWIE KONJUGATE DERSELBEN.
NZ508381A (en) Antibodies, antagonists and agonists of the death domain containing receptor 5 (DR5)
CO4850562A1 (es) Proceso para producir una preparacion concentrada de anticuerpos
WO2000020864A8 (en) Immunotherapy of b cell involvement in progression of solid, nonlymphoid tumors
MD1374G2 (ro) Anticorpi monoclonali imunostimulatori, procedeu de obţinere a acestora, linii celulare, metodă de tratare a maladiilor şi compoziţie farmaceutică
UA102988C2 (ru) ВЫДЕЛЕННОЕ АНТИТЕЛО ЧЕЛОВЕКА ИЛИ ЕГО АНТИГЕН-СВЯЗЫВАЮЩАЯ ЧАСТЬ, КОТОРАЯ СВЯЗЫВАЕТ TNFα ЧЕЛОВЕКА, ФАРМАЦЕВТИЧЕСКАЯ КОМПОЗИЦИЯ, КОТОРАЯ ЕГО СОДЕРЖИТ, И СПОСОБ ЛЕЧЕНИЯ ЗАБОЛЕВАНИЯ, В КОТОРОМ АКТИВНОСТЬ TNFα ЯВЛЯЕТСЯ ВРЕДНОЙ
EP0746625A4 (de) Erzielbare vektorenpartikel
IL122211A0 (en) Modified/chimeric superantigens and their use
TNSN93012A1 (fr) Conception, clonage et expression d'anticorps monoclonaux humanises contre l'interleukine-5 humaine
SG96535A1 (en) Pharmaceutical composition for the treatment or prevention of a malignant tumor
NO994983L (no) Fremgangsmåte for fremstilling av anti-humane antigenreseptorer, samt anvendelse av disse
NL300418I1 (nl) Gebruik van trifunctionele bispecifieke en trispecifieke antilichamen voor de behandeling van maligne ascitis
DE3372175D1 (en) Covalent conjugates of an enzyme and an antibody, and medicinal compositions containing these conjugates
ZA891861B (en) Monoclonal antibodies
AU2002223462A1 (en) Use of cd28-specific monoclonal antibodies for stimulating blood cells that lackcd28
TR199800912T2 (xx) T�m�r a��s� ve a��n�n haz�rlanmas� i�in usul.
EP0090581A3 (de) Kleine, für Maul- und Klauenseuche spezifische Peptide
NZ333329A (en) Polypeptides capable of forming antigen binding structures with specificity for rhesus d antigens
EP0368668A3 (de) Antikörper-Arzneimittel Konjugale
AU641736B2 (en) Delivery of agents
MY103231A (en) Immunoglobulin conjugates
KR900011477A (ko) 항-트립타아제 항체 및 이것을 사용한 후천성 면역결핍증 치료용 조성물
McGuigan Binding of caerulein by antibodies to human gastrin I
Mikalauskene et al. Preparation of monoclonal antibodies to gp51 antigen and their use for early diagnosis of bovine leukemia
Hochkeppel et al. Delivery of Interferons to Target Cells by Monoclonal Antibodies: Potential for the Specific Targeting of Other Lymphokines